This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-51. (canceled)

52. (currently amended) A method of detecting a lysosomal storage disorder (LSD), monitoring the progress of a LSD or the efficacy of treatment of a LSD in a human or animal subject, the method comprising assaying the level of ~~a LSD marker~~ Lamp-1 (lysosome-associated membrane protein type-1) in a biological sample derived from the subject, wherein

the biological sample is a blood, serum, plasma or urine sample; and

~~the LSD marker is selected from the group consisting of Lamp-1 (lysosome-associated membrane protein type-1), 4-sulphatase and ß-hexosaminidase; and~~

an increase in the level of ~~the LSD marker~~ Lamp-1 in the subject relative to the corresponding level of ~~the LSD marker~~ Lamp-1 in a non-affected individual or population is indicative of a LSD.

53-54. (canceled)

55. (currently amended) The method according to claim 52, wherein the ~~LSD marker is Lamp-1~~ biological sample is a blood, plasma or urine sample.

56-57. (canceled)

58. (previously presented) The method according to claim 52, wherein the biological sample is a blood, plasma, or serum sample.

59. (currently amended) The method according to claim 55, wherein the biological sample is a blood~~, plasma, or serum~~ sample.

60. (currently amended) The method according to claim 55, wherein the biological sample is a ~~blood, plasma or~~ urine sample.

61-62. (canceled)

6 ~~63~~. (previously presented) The method according to claim ~~52~~ 1, wherein the LSD is selected from the list set forth in Table 1.

7 ~~64~~. (previously presented) The method according to claim ~~63~~ 6, wherein the LSD is selected from the group consisting of MPS I, MPS II, Gaucher disease, Pompe disease and Salla's disease.

8 ~~65~~. (currently amended) The method according to claim ~~52~~ 1, wherein the step of assaying the level of ~~a LSD marker~~ Lamp-1 comprises measuring the enzyme activity of ~~said LSD marker~~ Lamp-1 in the biological sample.

9 ~~66~~. (currently amended) The method according to claim ~~52~~ 1, wherein the step of assaying the level of ~~the LSD marker~~ Lamp-1 comprises contacting the biological sample with one or more antibodies specific for ~~the LSD marker~~ Lamp-1 for a time and under conditions sufficient for the ~~formulation~~ formation of a complex to occur.

G2

[67. (canceled)

10 ~~68~~. (previously presented) The method according to claim ~~66~~ 9, wherein the one or more antibodies are monoclonal antibodies.

11 ~~69~~. (previously presented) The method according to claim ~~66~~ 9, wherein the one or more antibodies is/are labeled with a reporter molecule.

12 ~~70~~. (currently amended) The method according to claim ~~66~~ 9, further comprising the step of contacting the complex formed between ~~the LSD marker~~ Lamp-1 and one of the one or more antibodies with a labeled antibody for a time and under conditions sufficient for binding to occur.

13 ~~71~~. (previously presented) The method according to claim ~~70~~ 12, wherein the labeled antibody is labeled with a reporter molecule.

14 ~~72~~. (previously presented) The method according to claim ~~69~~ 11, wherein the reporter molecule is an enzyme, a fluorophore or a radionuclide molecule.

14 15 ~~73~~. (previously presented) The method according to claim ~~72~~, wherein the enzyme, fluorophore or radionuclide molecule is selected from the group consisting of horseradish peroxidase, glucose oxidase, ß-galactosidase, alkaline phosphatase, fluorescein, Eu^{3+} and other lanthanide metals, and rhodamine.

16 ~~74~~. (currently amended) The method according to claim 1 ~~52~~, wherein

(a) the LSD is selected from the list set forth in Table 1;

~~(b) the LSD marker is LAMP-1;~~

~~(c)~~(b) the subject is a human; and

~~(d)~~(c) the biological sample is a human blood, plasma or urine sample.

75-92. (canceled)

17 ~~93~~. (previously presented) A method for detecting a lysosomal storage disorder (LSD), comprising assaying LAMP-1 (lysosome-associated membrane protein type-1) in a sample of blood obtained from a patient that is asymptomatic for a LSD, an increase in the level of LAMP-1 in the patient relative to the corresponding level of LAMP-1 in a non-affected individual or population being indicative of a LSD.

94. (canceled).

18 ~~95~~. (currently amended) A method of detecting a lysosomal storage disorder (LSD), monitoring the progress of a LSD or the efficacy of treatment of a LSD in a human or animal subject, the method comprising assaying the level of ~~a LSD marker~~ Lamp-1 in a biological sample derived from the subject, wherein

~~the LSD marker is selected from the group consisting of Lamp-1 (lysosome-associated membrane protein type-1), 4-sulphatase and β-hexosaminidase;~~

the LSD is selected from the group consisting of Galactosialidosis, Gaucher disease, CM1-gangliosidosis, α-Mannosidosis, Mucopolysaccharidosis (MPS) I, MPS II, MPS IIIA, MPS IIIB, MPS IIIC, MPS IIID, MPS IVA, MPS VI, Multiple sulphatase deficiency, Sandhoff disease, Sialic Acid Storage disease, Tay-Sachs disease, Wolman disease and Salla's disease; and

S2

6

an increase in the level of ~~the LSD marker~~ Lamp-1 in the subject relative to the corresponding level of the LSD marker in a non-affected individual or population is indicative of a LSD.

96. (canceled)

19 ~~97.~~ (previously presented) The method of claim ~~95~~ 18, wherein the LSD is selected from the group consisting of MPS I, MPS II, Gaucher disease, Pompe disease, and Salla's disease.

20 ~~98.~~ (previously presented) The method according to claim ~~95~~ 18, wherein the biological sample comprises blood, plasma, serum, urine, a fibroblast cell, a fibroblast cell culture or a fibroblast cellular extract.

21 ~~99.~~ (previously presented) The method according to claim ~~98~~ 20, wherein the fibroblast cell, fibroblast cell culture or fibroblast cellular extract is a Pompe, Salla, MPS II or MPS VI fibroblast cell, cell culture or cellular extract.

22 ~~100.~~ (previously presented) The method according to claim ~~98~~ 20, wherein the biological sample is a blood, plasma, serum or urine sample.

23 ~~101.~~ (previously presented) The method according to claim ~~96~~ 18 ~~95~~, wherein the subject is a human.

24 ~~102.~~ (currently amended) A method of detecting a lysosomal storage disorder (LSD), monitoring the progress of a LSD or the efficacy of treatment of a LSD in a human or animal subject, the method comprising assaying the level of Lamp-2 (lysosome-associated membrane protein type-2) in a biological sample derived from the subject, wherein

the LSD is selected from the group consisting of Pompe disease, Gaucher disease and a Mucopolysaccharidosis (MPS) disease; and

an increase in the level of ~~the LSD marker~~ Lamp-2 in the subject relative to the corresponding level of ~~the LSD marker~~ Lamp-2 in a non-affected individual or population is indicative of a LSD.

25 ~~103~~. (previously presented) The method of claim 24 ~~102~~, wherein the LSD is Gaucher disease or MPS I.

26 ~~104~~. (previously presented) The method of claim 24 ~~102~~, wherein the biological sample comprises blood, plasma, serum, urine, a fibroblast cell, a fibroblast cell culture or a fibroblast cellular extract.

9₂

27 ~~105~~. (previously presented) The method according to claim 26 ~~104~~, wherein the biological sample is a blood, plasma, serum or urine sample.

28 ~~106~~. (previously presented) The method according to claim 24 ~~102~~, wherein the subject is a human and the biological sample is a human blood, plasma, serum or urine sample.